Table 4.
Unmet needs for rehabilitation 14 months after diagnosis
| Physical area | Emotional area | Family oriented area | Sexual area | Work-related area | Financial area | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n = 922 | n = 883 | n = 380 | n = 454 | n = 222–230 | n = 230 | |||||||||||||
| n (%) | ORcrude | ORadja (95% CI) | n (%) | ORcrude | ORadja (95% CI) | n (%) | ORcrude | ORadja (95% CI) | n (%) | ORcrude | ORadja (95% CI) | n (%) | ORcrude | ORadja (95% CI) | n (%) | ORcrude | ORadja (95% CI) | |
| Unmet needs, total | 159 (17.3) | − | − | 209 (23.7) | − | − | 122 (32.1) | − | − | 225 (49.6) | − | − | 43 (18.7) | − | − | 79 (34.4) | − | − |
| Sex | ||||||||||||||||||
| Men | 63 (19.8) | 1.00 | 1.00 | 85 (31.1) | 1.00 | 1.00 | 43 (34.4) | 1.00 | 1.00 | 124 (46.8) | 1.00 | 1.00 | 18 (26.1) | 1.00 | 1.00 | 42 (39.3) | 1.00 | 1.00 |
| Women | 96 (15.9) | 0.76 | 0.96 (0.60–1.54) | 124 (20.3) | 0.56** | 0.58** (0.37–0.92) | 79 (31.0) | 0.86 | 1.06 (0.58–1.93) | 101 (53.4) | 1.31 | 0.80 (0.42–1.55) | 25 (15.5) | 0.52 | 0.53 (0.19–1.47) | 37 (30.1) | 0.67 | 0.53 (0.24–1.19) |
| Age (years) | ||||||||||||||||||
| <60 | 64 (15.3) | 1.00 | 1.00 | 91 (18.3) | 1.00 | 1.00 | 65 (26.9) | 1.00 | 1.00 | 105 (47.7) | 1.00 | 1.00 | 33 (16.6) | 1.00 | 1.00 | 53 (33.3) | 1.00 | 1.00 |
| ≥60 | 95 (18.9) | 1.29 | 1.17 (0.81–1.70) | 118 (30.7) | 1.98** | 2.05** (1.47–2.85) | 57 (41.3) | 1.92** | 2.03** (1.27–3.25) | 120 (51.3) | 1.15 | 1.83** (1.16–2.89) | 10 (32.3) | 2.40* | 2.98* (1.14–7.80) | 26 (36.6) | 1.16 | 1.08 (0.58–2.03) |
| Cancer diagnosis | ||||||||||||||||||
| Breast | 40 (12.1) | 1.00 | 1.00 | 55 (17.7) | 1.00 | 1.00 | 33 (26.4) | 1.00 | 1.00 | 54 (56.8) | 1.00 | 1.00 | 12 (14.1) | 1.00 | 1.00 | 19 (38.0) | 1.00 | 1.00 |
| Prostate | 16 (18.4) | 1.63 | 1.46 (0.65–3.27) | 24 (30.8) | 2.06* | 0.94 (0.45–1.97) | 7 (28.0) | 1.08 | 0.83 (0.26–2.62) | 51 (36.4) | 0.44** | 0.24** (0.10–0.56) | 2 (15.4) | 1.11 | 0.30 (0.04–2.35) | 10 (55.6) | 2.04 | 1.06 (0.27–4.13) |
| Colo-rectal | 28 (22.1) | 2.05** | 1.93* (1.07–3.48) | 18 (19.6) | 1.13 | 0.78 (0.41–1.49) | 16 (38.1) | 1.72 | 1.62 (0.72–3.68) | 29 (48.3) | 0.71 | 0.52 (0.23–1.17) | 4 (14.8) | 1.06 | 0.55 (0.13–2.36) | 6 (23.1) | 0.49 | 0.32 (0.09–1.08) |
| Gynecological | 14 (24.6) | 2.36* | 2.33* (1.17–4.65) | 17 (23.9) | 1.46 | 1.47 (0.79–2.74) | 10 (30.3) | 1.21 | 1.16 (0.49–2.72) | 16 (48.5) | 0.71 | 0.68 (0.30–1.52) | 5 (19.2) | 1.45 | 1.45 (0.45–4.62) | 6 (28.6) | 0.65 | 0.65 (0.21–1.96) |
| Malignant melanoma | 4 (9.8) | 0.78 | 0.75 (0.25–2.26) | 17 (37.8) | 2.81** | 2.51* (1.24–5.05) | 5 (31.3) | 1.27 | 1.29 (0.40–4.13) | 8 (72.7) | 2.02 | 1.68 (0.40–6.99) | 0 (0) | − | − | 3 (23.1) | 0.49 | 0.31 (0.07–1.46) |
| Lung | 15 (22.7) | 2.13* | 1.97 (0.97–4.01) | 16 (28.6) | 1.85 | 1.31 (0.66–2.60) | 10 (40.0) | 1.86 | 1.46 (0.57–3.72) | 14 (66.7) | 1.52 | 1.13 (0.39–3.27) | 4 (50.0) | 6.08* | 4.02 (0.75–21.7) | 7 (43.8) | 1.27 | 0.86 (0.25–3.02) |
| Lymphoma | 7 (21.9) | 2.03 | 1.95 (0.76–5.00) | 15 (34.1) | 2.39* | 2.05 (0.99–4.27) | 9 (40.9) | 1.93 | 2.19 (0.81–5.89) | 8 (53.3) | 0.87 | 0.72 (0.22–2.36) | 2 (22.2) | 1.74 | 1.65 (0.29–9.26) | 4 (36.4) | 0.93 | 0.69 (0.17–2.88) |
| Head and neck | 9 (32.1) | 3.43** | 3.32** (1.34–8.22) | 13 (35.1) | 2.51* | 2.00 (0.90–4.43) | 6 (42.9) | 2.09 | 2.09 (0.64–6.85) | 7 (63.6) | 1.33 | 1.24 (0.32–4.81) | 4 (28.6) | 2.43 | 1.63 (0.36–7.29) | 6 (50.0) | 1.63 | 0.97 (0.23–4.10) |
| Other | 26 (16.9) | 1.47 | 1.41 (0.77–2.57) | 34 (22.7) | 1.36 | 0.98 (0.56–1.72) | 26 (33.3) | 1.39 | 1.48 (0.72–3.04) | 38 (55.9) | 0.96 | 0.77 (0.35–1.69) | 10 (25.0) | 2.03 | 1.25 (0.39–4.05) | 18 (28.6) | 0.65 | 0.43 (0.16–1.13) |
For each area (physical, emotional, family oriented, sexual, work-related, and financial) number, frequencies and crude and adjusted odds ratios (ORs) are shown with regard to sex, age, and cancer diagnosis.
aAdjusted for sex, age group, and cancer diagnosis
*p < 0.05
**p < 0.01